Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/01/24
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/20/24
Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene EditingSeeking Alpha • 01/28/24
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisGlobeNewsWire • 01/25/24
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CFBusiness Wire • 01/25/24
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should KnowZacks Investment Research • 01/10/24
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/03/23
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1bGlobeNewsWire • 10/27/23
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological DiseasesGlobeNewsWire • 10/24/23
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry ConferencesGlobeNewsWire • 10/17/23